Latest News Archive

Please select Category, Year, and then Month to display items

UFS welcomes GeoCongress 2025 delegates

02 June 2025 | Story Leonie Bolleurs | Photo Supplied

Dr Martin Clark, chair of the local organising committee, is looking forward to welcoming delegates to the GeoCongress.

In just more than three weeks, the University of the Free State (UFS) will open its doors to delegates attending GeoCongress 2025, hosted in collaboration with the Geological Society of South Africa. From 23 to 27 June 2025, academics, industry professionals, and students will come together on the Bloemfontein Campus to share knowledge, discuss new research, and connect with peers in the geosciences.

This biennial event will feature a dynamic programme of workshops, keynote addresses, and presentations covering a broad range of topics in the field.

Message from the event organisers and UFS leadership

“It is a unique honour to be able to host the national GeoCongress, being responsible for bringing together our partners in industry and academia to share our evolving understanding of the rocks, minerals, and advances in the geosciences and associated disciplines. My view of the GeoCongress stems from my appreciation and understanding of one of South Africa’s most highly regarded geologists, Dr Hans Merensky. Dr Merensky is credited with finding platinum in the Bushveld, diamonds in Namaqualand, and phosphorus and vermiculite in Phalaborwa. However, less remember was Dr Merensky’s ability to coordinate comprehensive investigations of rocks, and his tenacity in exploring across the South African landscape. For this, I believe our theme Embracing Change through Collaboration is apt, since it's through interactions between various sectors that we are best able to handle the challenges of tomorrow,” comments Dr Martin Clark, Senior Lecturer in the UFS Department of Geology and principal investigator of the Merensky Group for Airborne Geological Image Classification (MAGIC) at the Department of Geology.

“The 2025 GeoCongress symbolises the principles of sustainable research and innovation that we advocate for in the Faculty of Natural and Agricultural Sciences and underscores our dedication to the development of interdisciplinary collaboration. Research collaboration through our Green and Complex Research Hubs is consistent with the congress theme of ‘Embracing Change Through Collaboration’. By integrating geoscience research with broader sustainability and technological advancements, we guarantee that our scientific discoveries make a significant contribution to both environmental stewardship and industry," said Prof Paul Oberholster, Dean of the Faculty of Natural and Agricultural Sciences.

Outstanding line-up of attendees

GeoCongress 2025 is set to bring together some of the most influential minds in geoscience, creating a space where leading academics, industry experts, and emerging researchers can exchange ideas and insights. Attendees will have the opportunity to engage with key figures shaping the field, including Prof Glen Nwaila, Director of the Wits Mining Institute and a leading authority in economic geology and geometallurgy at the University of the Witwatersrand; Prof John Carranza, a highly regarded researcher at the UFS; and Sifiso Siwela, Chairperson of the SAMCODES Standards Committee and past president of the Geological Society of South Africa.

Adding to the wealth of expertise, Dr Geoffrey Howarth, Senior Lecturer at the University of Cape Town and Head of the Electron Microprobe Facility, will bring his knowledge in mineral studies, while Prof Susan Webb, Associate Professor of Geophysics at the University of the Witwatersrand and acting co-director of the DSI-NRF Centre of Excellence for Integrated Mineral and Energy Resource Analysis (CIMERA), will share her insights into geophysical research. Dr Hayley Cawthra, specialist scientist at the Council for Geoscience, will contribute her expertise in coastal geology, and Prof Steve McCourt, President of the Geological Society of South Africa and Professor Emeritus at the University of KwaZulu-Natal, will bring his experience in structural geology. The line-up also includes Prof Wolfgang Maier from Cardiff University, whose research on magmatic ore deposits continues to influence the field.

To make the most of your GeoCongress 2025 experience, be sure to take full advantage of the networking opportunities – from informal meet-and-greets to engaging panel discussions. Don't miss the chance to attend hands-on workshops and exciting field excursions. These excursions offer a deeper look into the country’s rich geological history, with opportunities to visit Florisbad, Kimberley, the Beatrix operations in the Goldfields, or the Drakensberg. For more tips on navigating the congress and must-see highlights, visit the GeoCongress 2025 website at https://geocongress2025.org.za/ or contact us at secretariat@geocongress2025.org.za.

GeoCongress 2025 is set to be a landmark event on the geosciences calendar. With the UFS as your host, prepare for an experience that combines academic excellence, innovation, and a collaborative spirit. Welcome to GeoCongress 2025!

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept